Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Exclusives

More »

For full access to this article login to GEN Select now.

Jan 16, 2014

What Is the Real Drug Development Cost for Very Small Biotech Companies?

A small biotech company, virtual or not, has nowhere near $2 billion to bring a drug to market. A simple calculation shows that it can be done for less than $250 million.

What Is the Real Drug Development Cost for Very Small Biotech Companies?

There are a growing number of companies with only one drug candidate in development and none on the market because of the rise of virtual companies. [Natalia Merzlyakova - Fotolia.com]

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.
    •  


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »